# Imatinib

## Leevk 100mg

| 藥物代碼 | OLEEV |
| :--- | :--- |
| 適應症 | Adult & pediatrics with newly diagnosed chronic myeloid leukemia \(CML\), CML in blast crisis, accelerated phase or chronic phase after failure of interferon-α therapy. Adult with newly diagnosed Philadelphia chromosome +ve acute lymphoblastic leukemia \(Ph+ALL\) integrated with chemotherapy; with relapsed or refractory Ph+ALL as montherapy; myelodysplastic/myeloproliferative diseases \(MDS/MPD\) associated with platelet-derived growth factor receptor \(PDGFR\) gene re-arrangements; systemic mastocytosis \(SM\) without D816V c-Kit mutation or with c-Kit mutation status unknown; hypereosinophilic syndrome \(HES\) &/or chronic eosinophilic leukemia \(CEL\); unresectable &/or metastatic, malignant GI stromal tumors \(GIST\); unresectable, recurrent &/or dermatofibrosarcoma protuberans \(DFSP\). |
| 副作用 | GI disturbances, anorexia, gastro-esophageal reflux, mouth ulceration, myalgia, muscle cramps, joint swelling, headache, dizziness, taste disturbance, paraesthesia, insomnia, conjunctivitis, increased lacrimation, blurred vision, epistaxis, dyspnea, weight gain, periorbital edema, dermatitis, rash, face & eyelid edema, pruritus, erythema, dry skin, alopecia, night sweats, fluid retention & edema, fatigue; pyrexia, weakness, rigors; neutropenia & febrile neutropenia, thrombocytopenia, anemia.Cardiovascular: Edema \(1.1% to 86.1% \)Dermatologic: Night sweats \(13% to 17% \), Rash \(up to 49.8% \)Endocrine metabolic: Weight gain \(up to 32% \)Gastrointestinal: Diarrhea \(3% to 58.2% \), Nausea \(3% to 73% \), Vomiting \(2% to 58% \)Musculoskeletal: Arthralgia \(12.3% to 40% \), Cramp \(up to 62% \), Musculoskeletal pain \(up to 49% \), Myalgia \(9% to 32.2% \)Neurologic: Asthenia \(15% to 21% \), Dizziness \(12% to 16% \), Headache \(up to 36% \), Insomnia \(10% to 14% \)Respiratory: Cough \(14% to 27% \), Nasopharyngitis \(10% to 30.5% \), Pain, Pharyngolaryngeal \(18.1% \), Pharyngitis \(10% to 15% \)Other: Fatigue \(25% to 48% \), Fever \(16.7% to 41% \), Influenza \(0.8% to 13.8% \), Rigor \(10% to 12% \) |
| 禁忌 | Hypersensitivity to imatinib or any component of the formulation |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | Human \(and animal\) data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

